Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Academic Article uri icon

Overview

abstract

  • Cancer-specific inhibitors that reflect the unique metabolic needs of cancer cells are rare. Here we describe Gboxin, a small molecule that specifically inhibits the growth of primary mouse and human glioblastoma cells but not that of mouse embryonic fibroblasts or neonatal astrocytes. Gboxin rapidly and irreversibly compromises oxygen consumption in glioblastoma cells. Gboxin relies on its positive charge to associate with mitochondrial oxidative phosphorylation complexes in a manner that is dependent on the proton gradient of the inner mitochondrial membrane, and it inhibits the activity of F0F1 ATP synthase. Gboxin-resistant cells require a functional mitochondrial permeability transition pore that regulates pH and thus impedes the accumulation of Gboxin in the mitochondrial matrix. Administration of a metabolically stable Gboxin analogue inhibits glioblastoma allografts and patient-derived xenografts. Gboxin toxicity extends to established human cancer cell lines of diverse organ origin, and shows that the increased proton gradient and pH in cancer cell mitochondria is a mode of action that can be targeted in the development of antitumour reagents.

publication date

  • March 6, 2019

Research

keywords

  • Glioblastoma
  • Oxidative Phosphorylation

Identity

PubMed Central ID

  • PMC6655586

Scopus Document Identifier

  • 85063281637

Digital Object Identifier (DOI)

  • 10.1038/s41591-018-0019-5

PubMed ID

  • 30842654

Additional Document Info

volume

  • 567

issue

  • 7748